Replies to post #7637 on RespireRx Pharmaceuticals Inc (fka RSPI)

[tonyvanw]

<<Cortex has been sitting in a dead calm for sixteen months>>

<I have seen quite the opposite, a very small company that has had to hit overdrive for much of the past sixteen months>

Most interesting how perceptions differ. Harry - Thanks for the perspective.

Tony

[ChetP1]

Following the FDA decision I anticipated a significant PR from Cortex giving insight into the next course of action and direction of the company.

This did not happen. I think the only explanation can be that whatever occurs next will involve a third party, or parties, and no announcement can be made until the details have been etched in stone and the partners choose to make public their own ambitions. Just because COR shareholders want publicity right now does not mean the BP's are of the same opinion.

Any thoughts to the contrary?

Chet

[RBlatch]

Neuro - Thank you for your response.

I believe that your comments can be filed under the "While I understand that it is never quite as simple as it may appear to be" portion of my statement. :)

However, not having the submission ready-to-go after knowing for the last sixteen months that it would be the next step in your life line is puzzling. Too busy? For what? You're busy. I'm busy. The whole world is busy. But we all find enough time to get done what absolutely needs to be done, don't we? And perhaps Cortex has also, but we don't know that at the moment. Thus my thought.

Perhaps the next announcement, or CC, will be one which makes my concern moot.

Cordially,
RBlatch

[ombowstring]

I asked Dr. Stoll about Neuro's expressed concern regarding developing the ADHD trial protocol now that Hank Mansbach has left Cortex.

His reply:

"John, Quite some time ago I publicly announced that Dr. Mansbach had left the company and that in the interim we were using Dr. Gary Tollefson MD, Ph.D., a board member who previously headed all of CNS for Eli Lilly, as a clinical consultant as well as outside clinicians to put together our next protocol. The principal investigator on the pilot ADHD study will also be the PI for the new study. Roger"

So it seems Dr. Stoll is not concerned about adequately and successfully putting together the protocol.